2019
Age-Related Macular Degeneration Preferred Practice Pattern®
Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Ying GS. Age-Related Macular Degeneration Preferred Practice Pattern®. Ophthalmology 2019, 127: p1-p65. PMID: 31757502, DOI: 10.1016/j.ophtha.2019.09.024.Peer-Reviewed Original ResearchAcademies and InstitutesAgedAngiogenesis InhibitorsColoring AgentsFemaleFluorescein AngiographyHumansIndocyanine GreenIntravitreal InjectionsLaser CoagulationMacular DegenerationMaleOphthalmologyPractice Patterns, Physicians'Quality of Health CareTomography, Optical CoherenceUnited StatesVascular Endothelial Growth Factor ARetinal Vein Occlusions Preferred Practice Pattern®
Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Ying GS. Retinal Vein Occlusions Preferred Practice Pattern®. Ophthalmology 2019, 127: p288-p320. PMID: 31757503, DOI: 10.1016/j.ophtha.2019.09.029.Peer-Reviewed Original ResearchInternational Practice Patterns for the Management of Acute Postsurgical and Postintravitreal Injection Endophthalmitis European Vitreo-Retinal Society Endophthalmitis Study Report 1
Soliman MK, Gini G, Kuhn F, Iros M, Parolini B, Ozdek S, Michalewska Z, Bopp S, Adelman RA, Sallam AB, Group E, Kardaszewska A, Zindamoyen A, Banker A, Serhiienko A, Loo A, Meireles A, Aydin B, Luebke B, Özmen C, Odrobina D, Bertelli E, Unsal E, Kenneth F, Becquet F, Hamon F, Pellegrini G, Tosi G, Donvito G, Khaqan H, Badat I, Fiser I, Michalewski J, Le Rouic J, Nawrocki J, Zarallo-Gallardo J, Lee J, Boninska K, Nowomiejska K, Dziegielewski K, Arrevola L, Lytvynchuk L, Elshafei M, Pietras-Trzpiel M, Irós M, Detjen M, Iglicki M, Badino M, Angelina M, Gavura M, Hasanreisoğlu M, Karadaş M, Atienza N, Acar N, Okonkwo O, Miesbauer P, Malgorzata P, Velez-Montoya R, Robert R, Frisina R, Soyeur R, Rejdak R, Giannini R, Mittal S, Saidkasimova S, Abdulsalam S, Cisiecki S, Rusnak S, Teoh S, Teixeira S, Altan T, Schrader W, Kapran Z, Aktas Z, Szijártó Z. International Practice Patterns for the Management of Acute Postsurgical and Postintravitreal Injection Endophthalmitis European Vitreo-Retinal Society Endophthalmitis Study Report 1. Ophthalmology Retina 2019, 3: 461-467. PMID: 31043364, DOI: 10.1016/j.oret.2019.03.009.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiogenesis InhibitorsAnti-Bacterial AgentsAntibiotic ProphylaxisCataract ExtractionDisease ManagementEndophthalmitisEuropeEye Infections, BacterialFemaleFollow-Up StudiesHumansIncidenceIntravitreal InjectionsMaleMiddle AgedOphthalmologyPractice Guidelines as TopicRetrospective StudiesSocieties, MedicalSurgical Wound InfectionVitrectomyConceptsEarly pars plana vitrectomyPars plana vitrectomyIntravitreal injectionIntravitreal antibioticsAcute endophthalmitisPlana vitrectomyIntraocular surgeryCataract surgeryPractice patternsAbsence of endophthalmitisSecond intravitreal injectionSecondary lens implantationProportion of eyesInternational practice patternsAcute postoperativeSystemic steroidsIntravitreal steroidsLens implantationAdjunctive therapySystemic antibioticsPostinjection endophthalmitisMulticenter studyRetina specialistsTherapeutic regimensVitreous opacification
2017
Age‐related macular degeneration: using morphological predictors to modify current treatment protocols
Ashraf M, Souka A, Adelman RA. Age‐related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmologica 2017, 96: 120-133. PMID: 29130626, DOI: 10.1111/aos.13565.Peer-Reviewed Original ResearchConceptsAge-related macular degenerationPigment epithelial detachmentChoroidal neovascular membranePosterior vitreous detachmentNeovascular age-related macular degenerationRetinal angiomatous proliferationSubretinal fluidIntraretinal cystsVitreomacular adhesionVisual outcomeVisual acuityPrognostic indicatorMacular degenerationAnti-vascular endothelial growth factorLarger choroidal neovascular membranesWet age-related macular degenerationOlder ageCNV sizeFinal visual outcomeGood visual outcomeAnti-VEGF therapyPoor prognostic indicatorCurrent treatment protocolsEndothelial growth factorInjection frequency
2016
Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients
Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. Ophthalmology 2016, 124: 352-358. PMID: 27890437, DOI: 10.1016/j.ophtha.2016.10.036.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiogenesis InhibitorsBevacizumabCohort StudiesDatabases, FactualDiabetic RetinopathyDrug UtilizationFemaleHumansInsurance, HealthIntravitreal InjectionsMacular DegenerationMaleMedicare Part CMiddle AgedOphthalmologyPrivate SectorRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal Vein OcclusionRetrospective StudiesUnited StatesVascular Endothelial Growth Factor AYoung AdultConceptsAge-related macular degenerationDiabetic retinal diseaseAnti-VEGF injectionsIntravitreal anti-VEGF injectionsRetinal vein occlusionAdministrative claims dataRetinal diseasesOphthalmic diseasesVein occlusionClaims dataUse of bevacizumabCurrent Procedural Terminology codesPatients 18 yearsRetrospective cohort studyMedicare Advantage patientsOptumLabs Data WarehouseDrug Administration approvalProcedural Terminology codesGrowth factor useRanibizumab useBevacizumab useAvailable medicationsCohort studyMedication useCommon medicationsAflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option
Ashraf M, Souka A, Adelman R, Forster SH. Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye 2016, 30: 1531-1541. PMID: 27564719, PMCID: PMC5177746, DOI: 10.1038/eye.2016.174.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaMacular edemaLarge phase 3 trialsBetter baseline VAEfficacy of afliberceptRole of afliberceptSecondary therapeutic optionsPhase 3 trialProtocol TBaseline VABimonthly regimenNata protocolAnatomic outcomesTherapeutic optionsPoor visionTreatment strategiesPrimary drugAfliberceptDifferent dosesDoseRanibizumabRegimenEdemaPatientsRecent dataPredicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature
Ashraf M, Souka A, Adelman R. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. British Journal Of Ophthalmology 2016, 100: 1596. PMID: 27231313, DOI: 10.1136/bjophthalmol-2016-308388.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaOptical coherence tomographyMacular edemaAnti-vascular endothelial growth factor therapyIntravitreal anti-vascular endothelial growth factorAnti-vascular endothelial growth factorEndothelial growth factor therapyFluorescein angiography findingsAnti-VEGF therapyAnti-VEGF agentsGrowth factor therapyCourse of treatmentCommon prognostic indicatorsEndothelial growth factorFactor therapyMost patientsVisual outcomeAngiography findingsChoroidal thicknessLarge RCTsTreatment regimenOCT parametersVisual acuityPrognostic indicatorDifferent RCTs
2013
Incidence and Management of Elevated Intraocular Pressure with Antivascular Endothelial Growth Factor Agents
Abedi G, Adelman RA, Salim S. Incidence and Management of Elevated Intraocular Pressure with Antivascular Endothelial Growth Factor Agents. Seminars In Ophthalmology 2013, 28: 126-130. PMID: 23631423, DOI: 10.3109/08820538.2013.771195.Peer-Reviewed Original ResearchConceptsPersistent ocular hypertensionIntraocular pressureOcular hypertensionIntravitreal antivascular endothelial growth factorAntivascular endothelial growth factor agentsChronic intraocular pressure elevationEndothelial growth factor agentsIntravitreal anti-VEGF injectionsAntivascular endothelial growth factorAnti-VEGF injectionsGrowth factor agentsIntraocular pressure elevationElevated intraocular pressureElectronic literature searchEndothelial growth factorKey search termsFactor agentsPrompt diagnosisVEGF injectionAcute elevationIntravitreal injectionIOP elevationPersistent elevationPressure elevationGlaucomatous eyes
2012
Intravitreal Ranibizumab for Treatment of Choroidal Neovascularization Secondary to Angioid Streaks in Pseudoxanthoma Elasticum: Five-year Follow-up
Zebardast N, Adelman RA. Intravitreal Ranibizumab for Treatment of Choroidal Neovascularization Secondary to Angioid Streaks in Pseudoxanthoma Elasticum: Five-year Follow-up. Seminars In Ophthalmology 2012, 27: 61-64. PMID: 22784267, DOI: 10.3109/08820538.2012.680644.Peer-Reviewed Original ResearchConceptsChoroidal neovascularizationOptical coherence tomographyPseudoxanthoma elasticumFluorescein angiographyNeovascular activityTreatment of CNVIntravitreal ranibizumab injectionsFive yearsMacular choroidal neovascularizationLong-term effectivenessOCT evidenceIntravitreal ranibizumabRanibizumab injectionsRanibizumab therapyAffected eyeIntraretinal fluidVisual acuityFluorescein leakageAngioid streaksScar formationInitial injectionCoherence tomographyRanibizumabInjectionNeovascularizationIs Intravitreal Bevacizumab an Effective Treatment Option for Nonarteritic Anterior Ischemic Optic Neuropathy?
Prescott CR, Sklar CA, Lesser RL, Adelman RA. Is Intravitreal Bevacizumab an Effective Treatment Option for Nonarteritic Anterior Ischemic Optic Neuropathy? Journal Of Neuro-Ophthalmology 2012, 32: 51-53. PMID: 22269947, DOI: 10.1097/wno.0b013e318240596e.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabFemaleHumansMaleMiddle AgedOptic Neuropathy, IschemicRetrospective StudiesVision, LowConceptsNonarteritic anterior ischemic optic neuropathyAnterior ischemic optic neuropathyIschemic optic neuropathyVisual acuityIntravitreal bevacizumabOptic neuropathyTreatment optionsIntravitreal bevacizumab injectionEffective treatment optionVisual field defectsBevacizumab injectionFellow eyesClinical outcomesRetrospective studyTreatment modalitiesNatural courseField defectsPatientsDecreased acuitySmall seriesAcuityBevacizumabProfound lossVisual fieldNeuropathy
2009
Minimal Effects of VEGF and Anti-VEGF Drugs on the Permeability or Selectivity of RPE Tight Junctions
Peng S, Adelman RA, Rizzolo LJ. Minimal Effects of VEGF and Anti-VEGF Drugs on the Permeability or Selectivity of RPE Tight Junctions. Investigative Ophthalmology & Visual Science 2009, 51: 3216-3225. PMID: 20042644, PMCID: PMC2891474, DOI: 10.1167/iovs.09-4162.Peer-Reviewed Original ResearchAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabBlood-Retinal BarrierCapillary PermeabilityCells, CulturedClaudinsElectric ImpedanceEnzyme-Linked Immunosorbent AssayFluorescent Antibody Technique, IndirectGene ExpressionHumansImmunoblottingPolyethylene GlycolsPotassiumRanibizumabRetinal Pigment EpitheliumReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSodiumTight JunctionsVascular Endothelial Growth Factor A
2008
Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefe's Archive For Clinical And Experimental Ophthalmology 2008, 247: 171. PMID: 18781316, DOI: 10.1007/s00417-008-0936-y.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAptamers, NucleotideBevacizumabChoroidal NeovascularizationDisease Models, AnimalDose-Response Relationship, DrugFluorescein AngiographyInjectionsLight CoagulationMacular DegenerationRanibizumabRatsRats, Inbred BNVascular Endothelial Growth Factor AVitreous BodyConceptsLeakage of CNVTreatment of CNVPegaptanib sodiumChoroidal neovascularizationIntravitreal injectionRat modelBackgroundVascular endothelial growth factorAnti-VEGF agentsEffect of bevacizumabAnti-VEGF medicationsBrown Norway ratsEndothelial growth factorNon-human primatesAngiography 1Histopathologic toxicityIntravitreal bevacizumabCNV leakageFluorescein angiographyLaser photocoagulationBevacizumabTherapeutic effectCNV lesionsRanibizumabDay 1Important stimulator
2007
Choroidal Neovascularization Associated with West Nile Virus Chorioretinitis
Seth RK, Stoessel KM, Adelman RA. Choroidal Neovascularization Associated with West Nile Virus Chorioretinitis. Seminars In Ophthalmology 2007, 22: 81-84. PMID: 17564926, DOI: 10.1080/08820530701418375.Peer-Reviewed Original ResearchConceptsWest Nile virus chorioretinitisChoroidal neovascularizationChoroidal Neovascularization AssociatedLate-onset complicationsBest therapeutic optionGood anatomical responseNeovascularization AssociatedDiabetes mellitusLeft eyeIntravitreal injectionTherapeutic optionsChorioretinitisNeovascularizationBevacizumabPatientsInjectionMellitusComplicationsBaseline